Asuka Pharma Holdings (4886) Earnings Report: Operating Income Decreased by 51.4% YoY to 711 Million Yen

Asuka Pharma Holdings (4886) announced its financial results for the latest quarter, reporting an operating income decrease of 51.4% year-on-year to 711 million yen. Net sales were 17,384 million yen (down 1.5% year-on-year), ordinary income was 817 million yen (down 48.7% year-on-year), and net income attributable to owners of the parent was 533 million yen (down 57.5% year-on-year). Meanwhile, comprehensive income showed a significant increase, rising 90.7% year-on-year to 1,413 million yen.

From a financial and valuation perspective, the company maintains a solid financial foundation with an equity ratio of 64.4%. Retained earnings stand at 62.98 billion yen, which compares favorably against interest-bearing debt of 11.83 billion yen, reflecting a sound balance sheet. Regarding profitability metrics, the Return on Equity (ROE) is 0.84%, the Return on Assets (ROA) is 0.48%, and EBITDA stands at 710 million yen, highlighting the ongoing focus on capital efficiency amidst current profit levels.